FOUND: Biib - What They Never Told You

Is Biogen Stock Outperforming the S&P 500?

Biogen has outpaced the broader S&P 500 Index over the past year, and analysts remain reasonably upbeat about the stock’s prospects.

Barchart · Sep 16

Is Wall Street Bullish or Bearish on Biogen Stock?

Biogen has notably outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart · Aug 20

Biogen's Q2 2026 Earnings: What to Expect

Biogen is poised to announce its second-quarter results later this month, and analysts predict a double-digit drop in the company’s bottom-line figure.

Barchart · Jul 9

Biogen Earnings Preview: What to Expect

Biogen is poised to announce its first-quarter results next week, and analysts predict a marginal drop in the company’s bottom-line figure.

Barchart · Apr 20

Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?

Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed.

Barchart · Mar 31

Biogen Stock: Is BIIB Outperforming the Healthcare Sector?

Biogen has outperformed its sector peers recently, and analysts remain moderately optimistic about the stock’s prospects.

Barchart · Mar 11

What Are Wall Street Analysts' Target Price for Biogen Stock?

Analysts are maintaining a generally positive outlook on Biogen's shares, noting recent stock strength and solid operational results.

Barchart · Feb 16

3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026

These three biotech stocks combine scale, late-stage pipelines, and analyst confidence, giving investors compelling upside potential in 2026

MarketBeat · Jan 20

What to Expect From Biogen's Next Quarterly Earnings Report

Biogen is expected to announce its fiscal fourth-quarter earnings soon, and analysts project a double-digit earnings drop.

Barchart · Jan 14

Is Biogen Stock Outperforming the Dow?

Biogen has notably outpaced the Dow in recent months and over the past year, and analysts remain moderately bullish on the stock’s prospects.

Barchart · Dec 8, 2025